John M. Pagel

Statistics

Publications

Citations

912

H-Index

Active since

2018

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Columbia University Irving Medical Center

Cleveland Clinic

Levine Cancer Institute

Fred Hutch Cancer Center

John M. Pagel is an author at Memorial Sloan Kettering Cancer Center specializing in chronic lymphocytic leukemia therapy, hematologic malignancy therapy, and immunotherapy.

Publications per year

2018–2023

Publications

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 318 citations · Full text

Pharmacy, Health Sciences, Internal Medicine +3

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Anthony R. Mato, Meghan C. Thompson, John N. Allan et al. · Haematologica · 2018 · 165 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey E. Roeker, Christopher P. Fox, Toby A. Eyre et al. · Clinical Cancer Research · 2019 · 90 citations · Full text

Pharmacy, Pharmacotherapy, Cancer Drug Toxicity Management +16

Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial

Anthony R. Mato, Lindsey E. Roeker, John N. Allan et al. · American Journal of Hematology · 2018 · 72 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster et al. · Blood · 2020 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

1–5 of 17